Success Metrics

Clinical Success Rate

50.0%

Based on 1 completed trials

Completion Rate

50%(1/2)

Active Trials

2(40%)

Results Posted

0%(0 trials)

Terminated

1(20%)

Phase Distribution

Ph phase_3

20%

Ph phase_1

80%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 1Safety & dosage

4(80.0%)

Phase 3Large-scale testing

1(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(2)

Completed(1)

Terminated(2)

Detailed Status

Recruiting1

Completed1

Active, not recruiting1

Terminated1

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

50.0%

Most Advanced

Phase 3

Trials by Phase

Phase 14 (80.0%)

Phase 31 (20.0%)

Trials by Status

recruiting120%

completed120%

active_not_recruiting120%

terminated120%

withdrawn120%

Recent Activity

2 active trials

Showing 5 of 5

active_not_recruitingphase_1

Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma

NCT05813327

recruitingphase_3

Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)

NCT05712694

completedphase_1

Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma

NCT03922880

terminatedphase_1

Study ADI-PEG 20 Plus Pembrolizumab in Advanced Solid Cancers

NCT03254732

withdrawnphase_1

Study in Patients With Tumours Requiring Arginine to Assess ADI-PEG 20 With Atezolizumab, Pemetrexed and Carboplatin

NCT03498222

Clinical Trials (5)

Showing 5 of 5 trials

NCT05813327Phase 1

Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma

Active Not Recruiting

NCT05712694Phase 3

Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)

Recruiting

NCT03922880Phase 1

Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma

Completed

NCT03254732Phase 1

Study ADI-PEG 20 Plus Pembrolizumab in Advanced Solid Cancers

Terminated

NCT03498222Phase 1

Study in Patients With Tumours Requiring Arginine to Assess ADI-PEG 20 With Atezolizumab, Pemetrexed and Carboplatin

Withdrawn

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5